Last reviewed · How we verify
NCT06027021: ARTE-MISO
Assessment of Hypoxia Before Radioembolization Treatment With 18F-FMISO PET
trial testing 18F-Fluoromisonidazole PET in Radioembolization in 64 participants. Completed in 15 July 2024.
15 May 2024
Quick facts
| Lead sponsor | Ankara University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 64 |
| Start date | 15 August 2023 |
| Primary completion | 15 May 2024 |
| Estimated completion | 15 July 2024 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- 18F-Fluoromisonidazole PET
Conditions studied
- Radioembolization — all drugs for Radioembolization →
- Radiotherapy — all drugs for Radiotherapy →
- Cancer — all drugs for Cancer →
- Positron Emission Tomography — all drugs for Positron Emission Tomography →
Sponsor
Ankara University
Who can join
18 and older, any sex, with Radioembolization or Radiotherapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Hypoxia is a known factor for resistance to radiotherapy in tumors. Response to transarterial radioembolization is known to be variable between different patients even if the same dose of radiation was delivered. In this study the investigators aim to quantify the hypoxia in the primary and secondary tumors of liver with 18F-FMISO PET before radioembolization and to prove any effect of the hypoxia, if present, on the dose that should be delivered to tumor to ensure treatment response.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Emerging PET Imaging Agents and Targeted Radioligand Therapy: A Review of Clinical Applications and Trials.
Palihati M, Das JP, Yeh R, Capaccione K. · · 2025 · cited 5× · PMID 40863874 · DOI 10.3390/tomography11080083
Verify or expand the search:
- PubMed search for NCT06027021
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Radioembolization
Currently open trials in the same condition.
- NCT07476651 — Scout Dose of Resin Microspheres · NA · recruiting
- NCT06773845 — Building Evidence for Ablative Internal Radiation Therapy in Localized HCC Beyond the Up-To-7 Criteria · Phase 2 · recruiting
- NCT07278102 — A Prospective Observational Study on Efficacy of TARE for Early Stage HCC · active not recruiting
Other Ankara University trials
Trials by the same sponsor.
- NCT07441837 — Terbium 161 PSMA in Lutetium-177 PSMA Naive Patients · Phase 2 · not yet recruiting
- NCT07536490 — Sleep Quality, Cognition, and Disease Severity in Parkinson's Disease · not yet recruiting
- NCT06959433 — Lu-177 PSMA Treatment in Cell Renal Carcinoma · Phase 3 · not yet recruiting
- NCT07513272 — EFFECT OF BALLS ON PAIN AND ANXIETY DURING VENIPUNCTURE IN CHILDREN · NA · not yet recruiting
- NCT07536542 — Effects of Dual-Task Training on Upper Extremity Function in Parkinson's Disease · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06027021 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ankara University
- Last refreshed: 30 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06027021.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing